<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629757</url>
  </required_header>
  <id_info>
    <org_study_id>CSNO2015001</org_study_id>
    <nct_id>NCT02629757</nct_id>
  </id_info>
  <brief_title>A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas</brief_title>
  <acronym>β-elemene</acronym>
  <official_title>A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to help determine whether β-elemene as maintain treatment for&#xD;
      complete remission patients of newly diagnosed malignant gliomas following standard&#xD;
      treatment, is able to delay tumor growth, or impact how long people with newly diagnosed&#xD;
      high-grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to help determine whether β-elemene as maintain treatment for&#xD;
      complete remission patients of newly diagnosed malignant gliomas following standard&#xD;
      treatment, is able to delay tumor growth, or impact how long people with newly diagnosed&#xD;
      high-grade glioma. β-elemene will be given 600mg/d,d1-14,q28 days for 6 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over-all survival</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>β-elemene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>β-elemene</intervention_name>
    <description>β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles</description>
    <arm_group_label>β-elemene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Page 3 of 4 [DRAFT] - Arms Assigned Interventions&#xD;
&#xD;
               -  Temodar Experimental: temozolomide +α-IFN Four weeks after radiotherapy, patients&#xD;
                  will be received 6 cycle of temozolomide plus α-IFN α-IFN： 3mIU (3million)&#xD;
                  Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study&#xD;
                  cycle and 200 mg/m^2 daily of subsequent cycles Drug: Temozolomide dosed at 200&#xD;
                  mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated&#xD;
                  every 28 days&#xD;
&#xD;
        Other Names:&#xD;
&#xD;
        • Temodar Drug: α-IFN 3mIU (3million) D1，3，5&#xD;
&#xD;
        Other Names:&#xD;
&#xD;
        Minimum Age: 18 Years Maximum Age: 75 Years Gender: Both Accepts Healthy Volunteers?: No&#xD;
&#xD;
        Criteria: Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years to 75 years&#xD;
&#xD;
          -  complete remission patients of newly diagnosed WHO III-IV glioma following standard&#xD;
             treatment&#xD;
&#xD;
          -  Karnofsky Performance Score ≥ 60&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  anticipating survival ≥2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate the study&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to temozolomide&#xD;
&#xD;
          -  Incompletely radiation&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Malignant tumor other than brain tumor&#xD;
&#xD;
          -  Contraindicated for MRI examination&#xD;
&#xD;
          -  Unable to comply with the follow-up studies of this trial&#xD;
&#xD;
          -  Purulent and chronic infected wounds&#xD;
&#xD;
          -  Uncontrolled psychotic disorders or epilepsy&#xD;
&#xD;
          -  progression disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-ping CHEN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong-ping CHEN</last_name>
    <phone>+86-20-87343310</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengceng Guo</last_name>
    <phone>+86-20-87343890</phone>
    <email>guochch@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-ping Chen</last_name>
      <phone>+86-20-87343310</phone>
    </contact>
    <contact_backup>
      <last_name>Chengcheng Guo</last_name>
      <phone>+86-20-87343890</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>High-grade glioma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>β-elemene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

